A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer

Journal of Translational Medicine ◽

10.1186/1479-5876-6-65 ◽

2008 ◽

Vol 6 (1) ◽

Cited By ~ 1

Author(s):

Alessandro Passardi ◽

Lorenzo Cecconetto ◽

Monia Dall'Agata ◽

Claudio Dazzi ◽

Enzo Pasquini ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non–Small-Cell Lung Cancer

Clinical Lung Cancer ◽

10.1016/j.cllc.2016.05.011 ◽

2017 ◽

Vol 18 (1) ◽

pp. 43-49 ◽

Cited By ~ 16

Author(s):

Fred R. Hirsch ◽

Ramaswamy Govindan ◽

Zanete Zvirbule ◽

Fadi Braiteh ◽

Achim Rittmeyer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Small Cell ◽

Controlled Study ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

Platinum Doublet

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801

The Oncologist ◽

10.1634/theoncologist.2020-0322 ◽

2020 ◽

Vol 25 (8) ◽

Author(s):

Koichi Takayama ◽

Masafumi Takeshita ◽

Koji Inoue ◽

Masao Ichiki ◽

Masaki Fujita ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)

Annals of Oncology ◽

10.1093/annonc/mdz437.046 ◽

2019 ◽

Vol 30 ◽

pp. ix175-ix176

Author(s):

K. Baba ◽

H. Tanaka ◽

Y. Fujita ◽

A. Nakamura ◽

E. Kikuchi ◽

...

Keyword(s):

Lung Cancer ◽

Maintenance Therapy ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Extensive Disease ◽

Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7628 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7628-7628 ◽

Cited By ~ 1

Author(s):

S. Nagel ◽

A. Groeschel ◽

M. Sebastian ◽

S. Andreas ◽

T. Mueller ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdm474 ◽

2008 ◽

Vol 19 (2) ◽

pp. 362-369 ◽

Cited By ~ 195

Author(s):

R. Rosell ◽

G. Robinet ◽

A. Szczesna ◽

R. Ramlau ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule

Lung Cancer ◽

10.1016/j.lungcan.2004.08.012 ◽

2005 ◽

Vol 47 (3) ◽

pp. 405-412 ◽

Cited By ~ 18

Author(s):

Elisabeth Quoix ◽

Jean-Luc Breton ◽

Alain Ducoloné ◽

Bertrand Mennecier ◽

Alain Depierre ◽

...

Keyword(s):

Lung Cancer ◽

Elderly Patients ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7603 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7603-7603 ◽

Cited By ~ 6

Author(s):

G. K. Dy ◽

S. J. Mandrekar ◽

G. D. Nelson ◽

H. J. Ross ◽

R. H. Ansari ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii Study of Belotecan or Topotecan Chemotherapy As Second-Line Chemotherapy After Platinum-Based First-Line Chemotherapy for Small Cell Lung Cancer

Annals of Oncology ◽

10.1093/annonc/mdu355.12 ◽

2014 ◽

Vol 25 ◽

pp. iv515 ◽

Cited By ~ 1

Author(s):

S. Yoon ◽

D.H. Lee ◽

C. Choi ◽

J.C. Lee ◽

J.S. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

P2-301: Gemcitabine - Cisplatin (GC) doublet chemotherapy in the first line treatment of the patients (Pts) with advanced non- small cell lung cancer (NSCLC): A phase II study

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284009.49630.d2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S692

Author(s):

Salim Reza ◽

Qamruzzaman Chowdhury ◽

Abdul Hai

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Doublet Chemotherapy ◽

First Line Treatment